Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Quantifying Uric Acid Excretion With RDEA3170, Febuxostat and Dapagliflozin

NCT03316131 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03316131
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03316131 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Quantifying Uric Acid Excretion With RDEA3170, Febuxostat and Dapagliflozin
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Completed
Start date
October 25, 2017
Completion date
July 19, 2018
Enrollment
36 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

asymptomatic hyperuricemia